Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Daniel Ambinder

Interventional & Structural Cards · UMSOM

View

Dr. Amit Goyal

Interventional & Structural Cards · UT Southwestern

View

Dr. David Cohen

Interventional & Structural Cards · Cardiovascular Research Foundation

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Brahmajee Nallamothu

Interventional Cardiology · UMHS

View

Dr. Felix Yang

EP · NYU Langone

View

Dr. Jennifer Rymer

Interventional & Peripheral Cards · Duke University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.

    Jun 3, 2026DOI: 10.1161/circinterventions.125.016370Journal ArticleAHA

    Written by: Kashish GoelBrian R LindmanAllan SchwartzDavid J CohenGennaro GiustinoJ Bradley OldemeyerJustin StroteVasilis BabaliarosChandan M DevireddyMichael P FischbeinWilliam F FearonDavid DanielsChristian SpiesAdnan K ChhatriwallaHussam S SuradiPinak ShahMolly SzerlipThom DahleDimitrios ApostolouRaj MakkarCharles J DavidsonTej ShethPaul SorajjaJames T DeVriesJeffrey SouthardJeremiah P DeptaAndrei PopMichael J RinaldiSalem BadrMathew R WilliamsMark J RussoMayra GuerreroJames M McCabePhilippe PibarotYizhuo WangMartin B LeonPhilippe Généreux

    Find these authors on Roon

    AP
    Dr. Andrei Pop
    Interventional & Structural Cards · Alexian Brothers

    Summary

    BACKGROUND: The EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) in asymptomatic severe aortic stenosis. The relative impact of early TAVR versus a CS strategy by age is unknown.METHODS: The study population of the EARLY TAVR trial was stratified into 4 age groups: 65 to 69 years (n=141), 70 to 74 years (n=263), 75 to 79 years (n=250), and ≥80 years (n=247). Associations between age and the trial primary end point of death, stroke, or unplanned cardiovascular hospitalization; the composite end point of death, stroke, or heart failure hospitalization; and its individual components were examined. Interaction tests evaluated whether the treatment effect of early TAVR versus CS differed by age.RESULTS: No interaction was detected between age and the treatment effect of early TAVR versus CS for the composite or individual outcomes. We observed lower stroke rates with early TAVR compared with CS in the youngest (65-69 years, absolute risk reduction, 13%; P=0.008) and oldest (≥80 years; absolute risk reduction, 12.3%; P=0.029) age groups. The absolute difference in heart failure hospitalization rates between the early TAVR and CS arms at 2 years was greatest in the oldest patients (≥80 years, 9.1%; 75-79 years, 5.9%; 70-74 years, 5.1%; 65-69 years, 4.4%). In the CS group, time to conversion to AVR was similar across all age groups (median, 11 months; P=0.73). Approximately one-third of younger patients (65-69 years) in the CS arm presented with acute valve syndrome at the time of conversion, and the frequency tended to increase with age (P=0.06).CONCLUSIONS: In the EARLY TAVR trial, the relative benefit of early TAVR over CS was consistent among all age groups. The greatest absolute reduction in stroke rate with early TAVR compared with CS appeared in the youngest and oldest groups, whereas reduction in heart failure hospitalization was most pronounced in the oldest patients. These data suggest that early TAVR should be considered in all age groups above 65 years.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03042104.
    APDr. Andrei Pop

    Dr. Andrei Pop

    Cardiology · Interventional Cardiology & Structural
    Alexian Brothers Medical Center
    andreip